Home/Indications/Renal/Chronic Kidney Disease

Chronic Kidney Disease

Renal 5 original drugs

Novel Drugs

Reformulations

Drug Targets

Renal indication. Chronic Kidney Disease has 5 FDA-approved novel treatments, led by KAI PHARMS INC, with 174 active industry clinical trials across 16 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Chronic Kidney Disease Market Leaders

Companies with the most FDA-approved novel Chronic Kidney Disease drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q4 2026

AND017 capsules

Kind Pharmaceuticals LLC

Estimated · fresh NCT07494409

Q4 2026

QRX-3

Ebima Clifford Okundaye

Estimated · aging NCT06866236

Q4 2026

MT1013

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Estimated · aging NCT07122401

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Chronic Kidney Disease Treatments by Mechanism

Top 12 mechanisms across 52 industry trials with a known mechanism of action.

See full pipeline →

Sodium-Glucose Cotransporter 2 Inhibitor

5 trials 1 active 2 sponsors

CaSR

4 trials 1 active 1 sponsor

Parenteral Iron Replacement

3 trials 1 active 1 sponsor

SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose

2 trials 1 active 1 sponsor

Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor

14 trials 1 sponsor

Vitamin D2 Analog

6 trials 3 sponsors

Erythropoiesis-stimulating Agent

5 trials 2 sponsors

ferric reductase/phosphate

4 trials 2 sponsors

SGLT2

3 trials 2 sponsors

Erythropoietin Receptor

2 trials 2 sponsors

GLP-1 Receptor Agonist

2 trials 2 sponsors

Glucose-dependent Insulinotropic Polypeptide Receptor Agonist

2 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Chronic Kidney Disease Clinical Pipeline by Phase

543 industry-sponsored trials across 181 sponsors

View full landscape →

Showing 30 of 30 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Ace Cells Lab Limited	ACE Reno	—	RECRUITING	2026-08-31	NCT07187713
Zydus Lifesciences Limited	Desidustat	—	RECRUITING	2025-06-30	NCT05515367
AstraZeneca	Dapagliflozin	SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose	ACTIVE NOT RECRUITING	2027-05-31	NCT06610526
Xuanzhu Biopharmaceutical Co., Ltd.	Anaprazole Sodium enteric-coated tablet	—	NOT YET RECRUITING	2026-10-30	NCT07345689
Shenzhen Salubris Pharmaceuticals Co., Ltd.	Enarodustat 2mg	—	NOT YET RECRUITING	2027-06	NCT07079579
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	ganagliflozin	—	NOT YET RECRUITING	2031-10-30	NCT07116928
Bayer	Finerenone (Kerendia, BAY94-8862)	—	COMPLETED	2025-07-03	NCT05705271
AstraZeneca	Sodium Zirconium Cyclosilicate (SZC)	—	COMPLETED	2024-12-10	NCT05347693
Ardelyx	Tenapanor	—	COMPLETED	2021-10-13	NCT04549597
AstraZeneca	Roxadustat	—	COMPLETED	2021-10-12	NCT04655027
Keryx Biopharmaceuticals	KRX-0502	—	COMPLETED	2019-08-30	NCT03236246
Sumitomo Pharma (Suzhou) Co., Ltd.	Arotinolol Hydrochloride	—	COMPLETED	2018-10-10	NCT01351636
Novartis	Induction therapy	—	COMPLETED	2017-02-01	NCT01950819
Amgen	Epoetin alfa	Erythropoietin Receptor	COMPLETED	2016-04-27	NCT02253654
AbbVie (prior sponsor, Abbott)	Paricalcitol	Vitamin D2 Analog [EPC]	COMPLETED	2016-04-07	NCT01506947
AMAG Pharmaceuticals, Inc.	Ferumoxytol	Parenteral Iron Replacement [EPC]	COMPLETED	2016-02	NCT01227616
Yuhan Corporation	Anplag(Sarpogrelate)	—	COMPLETED	2014-11-17	NCT01869881
Fresenius Medical Care Korea	—	—	COMPLETED	2014-04	NCT01997385
GE Healthcare	Omniscan	Paramagnetic Contrast Agent [EPC]	COMPLETED	2013-06	NCT00908310
Otsuka Beijing Research Institute	Probucol	—	COMPLETED	2012-12	NCT01252056
Fresenius Medical Care North America	Calcium acetate oral solution (COS)	—	COMPLETED	2012-07	NCT01427907
Guerbet	Dotarem®-enhanced MRI	—	COMPLETED	2011-05	NCT00650845
Abbott	Paricalcitol	Vitamin D2 Analog [EPC]	COMPLETED	2011-05	NCT00977080
Novo Nordisk	—	—	COMPLETED	2011-04	NCT01245374
Amgen	Cinacalcet	—	COMPLETED	2010-12-09	NCT00803712
Abbott	Zemplar (paricalcitol)	—	COMPLETED	2010-09	NCT00891813
Novartis	HX575 recombinant human erythropoietin alfa	—	COMPLETED	2010-03	NCT00632125
Ironwood Pharmaceuticals, Inc.	Lesinurad	—	TERMINATED	2019-02-25	NCT03226899
GE Healthcare	Visipaque	—	TERMINATED	2018-09-13	NCT03119662
B. Braun Melsungen AG	HES 130/0.42 + electrolyte solution	—	TERMINATED	2010-09	NCT00936247

Showing 100 of 166 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Kind Pharmaceuticals LLC	AND017 capsules	—	RECRUITING	2026-10-30	NCT07494409
Shaanxi Micot Pharmaceutical Technology Co., Ltd.	MT1013	—	RECRUITING	2026-11-26	NCT07122401
Kind Pharmaceuticals LLC	AND017	—	RECRUITING	2026-12-01	NCT07487727
Boehringer Ingelheim	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	RECRUITING	2027-04-16	NCT07107945
Renibus Therapeutics, Inc.	Veverimer	—	RECRUITING	2027-06	NCT07355062
Genexine, Inc.	Efepoetin Alfa	—	RECRUITING	2027-06	NCT06466785
Astellas	Roxadustat	—	RECRUITING	2027-10-30	NCT05970172
Bayer	Finerenone (Kerendia, BAY94-8862)	—	RECRUITING	2028-08-01	NCT05457283
Amgen	Etelcalcetide	CaSR	RECRUITING	2029-01-31	NCT03633708
Shandong Suncadia Medicine Co., Ltd.	HRS-1780 tablets	—	RECRUITING	2030-04	NCT07419828
AstraZeneca	Elecoglipron	—	RECRUITING	2030-10-04	NCT07753993
Eli Lilly	Orforglipron	—	RECRUITING	2031-08	NCT07241390
AMAG Pharmaceuticals, Inc.	Ferumoxytol	Parenteral Iron Replacement [EPC]	RECRUITING	2026-08-31	NCT03619850
Alebund Pharmaceuticals	AP301	—	RECRUITING	2026-06-20	NCT06933472
AstraZeneca	Zibotentan/Dapagliflozin	—	ACTIVE NOT RECRUITING	2027-02-18	NCT06087835
Bayer	Finerenone (Kerendia, BAY94-8862)	—	ACTIVE NOT RECRUITING	2027-04-10	NCT05196035
Eli Lilly	Retatrutide	—	ACTIVE NOT RECRUITING	2029-02	NCT06383390
Prokidney	Renal Autologous Cell Therapy (REACT/ rilparencel)	—	ACTIVE NOT RECRUITING	2029-12	NCT05099770
Biocad	BCD-131 (pegdarbepoetin beta)	—	ACTIVE NOT RECRUITING	2026-05-12	NCT07119372
Ebima Clifford Okundaye	QRX-3	—	NOT YET RECRUITING	2026-10	NCT06866236
Megalabs	Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration.	—	NOT YET RECRUITING	2027-03	NCT06352138
AstraZeneca	Balcinrenone/dapagliflozin	—	NOT YET RECRUITING	2030-07-01	NCT07624305
Shandong Suncadia Medicine Co., Ltd.	HRS-7535	—	NOT YET RECRUITING	2031-05	NCT07625774
Daewoong Pharmaceutical Co. LTD.	DWP16001 0.3mg	—	NOT YET RECRUITING	2026-09-01	NCT06606093
Akebia Therapeutics	Erythropoiesis-Stimulating Agent (ESA)	—	COMPLETED	2026-08-12	NCT06901505
Novo Nordisk	Ziltivekimab B	—	COMPLETED	2026-06-09	NCT05021835
Eli Lilly	Orforglipron	—	COMPLETED	2026-03-16	NCT05803421
Bayer	Finerenone (BAY94-8862)	—	COMPLETED	2025-12-31	NCT05047263
Vifor Fresenius Medical Care Renal Pharma	Patiromer Powder for Oral Suspension (Part A)	—	COMPLETED	2025-11-18	NCT05136664
Bayer	Finerenone	Nonsteroidal Mineralocorticoid-Receptor Antagonist [EPC]	COMPLETED	2025-08-20	NCT05901831
Novo Nordisk	Semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2024-11-21	NCT04865770
Alebund Pharmaceuticals	AP301	—	COMPLETED	2024-10-02	NCT07030595
Serodus AS	SER150	—	COMPLETED	2024-06-06	NCT04881123
Galderma R&D	Nemolizumab	—	COMPLETED	2024-01-04	NCT05075408
MediBeacon	MB-102	—	COMPLETED	2023-02-15	NCT05425719
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	COMPLETED	2023-01-06	NCT04707768
Nanogen Pharmaceutical Biotechnology Joint Stock Company	Stimus (NNG-DEPO)	—	COMPLETED	2022-11-23	NCT05585645
Panion & BF Biotech Inc.	Ferric citrate	ferric reductase/phosphate	COMPLETED	2022-10-28	NCT04543812
Boehringer Ingelheim	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2022-07-05	NCT03594110
PT Kalbe Genexine Biologics	efepoetin alfa	—	COMPLETED	2022-03-30	NCT04155125
Shenzhen Salubris Pharmaceuticals Co., Ltd.	SAL-0951	—	COMPLETED	2021-10-08	NCT06016036
Zydus Lifesciences Limited	Desidustat Oral Tablet	—	COMPLETED	2021-09-02	NCT04215120
Zydus Lifesciences Limited	Desidustat Oral Tablet	—	COMPLETED	2021-08-25	NCT04012957
Bio Sidus SA	Erythropoietin alfa	—	COMPLETED	2021-06-15	NCT04036253
Jiangsu Hansoh Pharmaceutical Co., Ltd.	Pegol-Sihematide	—	COMPLETED	2021-02-28	NCT03902691
JW Pharmaceutical	JTZ-951	—	COMPLETED	2021-02-23	NCT04027517
Bayer	Finerenone (BAY94-8862)	—	COMPLETED	2021-02-02	NCT02545049
Tanabe Pharma Corporation	Canagliflozin	SGLT2	COMPLETED	2021-01-21	NCT03436693
Vifor Fresenius Medical Care Renal Pharma	PA21	—	COMPLETED	2020-08-21	NCT03644264
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	COMPLETED	2020-06-18	NCT02680574
AstraZeneca	Dapagliflozin	SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose	COMPLETED	2020-06-12	NCT03036150
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	COMPLETED	2020-06-04	NCT02648347
Bayer	Finerenone (BAY94-8862)	—	COMPLETED	2020-04-14	NCT02540993
Amgen	Etelcalcetide	CaSR	COMPLETED	2020-04-08	NCT03299244
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	COMPLETED	2020-01-31	NCT02865850
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	COMPLETED	2020-01-16	NCT02892149
Boryung Pharmaceutical Co., Ltd	Fimsartan 60mg~120mg	—	COMPLETED	2019-12-23	NCT02620306
Astellas	roxadustat	—	COMPLETED	2019-09-13	NCT02988973
Bayer	Molidustat (BAY85-3934)	—	COMPLETED	2019-08-07	NCT03543657
Bayer	Molidustat (BAY85-3934)	—	COMPLETED	2019-07-25	NCT03418168
Bayer	Molidustat (BAY85-3934)	—	COMPLETED	2019-07-05	NCT03350347
Bayer	Molidustat (BAY85-3934)	—	COMPLETED	2019-05-17	NCT03350321
Lexicon Pharmaceuticals	Sotagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2019-05-16	NCT03242018
Lexicon Pharmaceuticals	Sotagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2019-03-25	NCT03242252
Tanabe Pharma Corporation	MT-6548	—	COMPLETED	2019-01-08	NCT03329196
Tanabe Pharma Corporation	MT-6548	—	COMPLETED	2018-12-12	NCT03439137
Tanabe Pharma Corporation	MT-6548	—	COMPLETED	2018-12-03	NCT03461146
Tanabe Pharma Corporation	MT-6548	—	COMPLETED	2018-11-22	NCT03402386
Johnson & Johnson	Canagliflozin	SGLT2	COMPLETED	2018-10-30	NCT02065791
Bayer	Molidustat (BAY85-3934)	—	COMPLETED	2018-10-23	NCT03351166
Astellas	roxadustat	—	COMPLETED	2018-08-15	NCT02964936
Pharmacosmos A/S	Iron isomaltoside/ferric derisomaltose	—	COMPLETED	2018-05-29	NCT02940860
Astellas	Roxadustat	—	COMPLETED	2018-03-23	NCT02021318
Astellas	roxadustat	—	COMPLETED	2018-03-13	NCT02952092
Proteon Therapeutics	Vonapanitase	—	COMPLETED	2018-02	NCT02414841
Shield Therapeutics	Ferric maltol	—	COMPLETED	2018-01-18	NCT02968368
Astellas	roxadustat	—	COMPLETED	2017-12-12	NCT02780141
Astellas	Roxadustat	—	COMPLETED	2017-11-01	NCT01887600
Amgen	Darbepoetin alfa	Erythropoiesis-stimulating Agent [EPC]	COMPLETED	2017-10-19	NCT01652872
Astellas	roxadustat	—	COMPLETED	2017-08-02	NCT02780726
Chong Kun Dang Pharmaceutical	CKD-11101	—	COMPLETED	2017-06	NCT03428594
Otsuka Pharmaceutical Development & Commercialization, Inc.	Tolvaptan (OPC-41061)	—	COMPLETED	2017-04-18	NCT02160145
Amgen	Cinacalcet	—	COMPLETED	2017-03-15	NCT02341417
Chong Kun Dang Pharmaceutical	CKD-11101(Darbepoetin alfa)	—	COMPLETED	2017-02	NCT03431623
Biocad	Darbepoetin alfa	Erythropoiesis-stimulating Agent [EPC]	COMPLETED	2017-01-08	NCT02506868
Proteon Therapeutics	PRT-201	—	COMPLETED	2016-12	NCT02110901
Pfizer	Epoetin Hospira Arm	—	COMPLETED	2016-07-02	NCT02504294
Eli Lilly	Dulaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2016-06	NCT01621178
Keryx Biopharmaceuticals	ferric citrate	ferric reductase/phosphate	COMPLETED	2016-01	NCT02268994
Novartis	Valsartan	Angiotensin 2 Receptor Blocker [EPC]	COMPLETED	2015-09	NCT01365481
OPKO Health, Inc.	CTAP101 Capsules	—	COMPLETED	2015-05	NCT02282813
Fresenius Medical Care Deutschland GmbH	Osvaren Granules	—	COMPLETED	2015-04	NCT02027662
Astellas	ASP1585	—	COMPLETED	2015-04	NCT01742611
Amgen	Etelcalcetide	CaSR	COMPLETED	2014-11-12	NCT01896232
Novartis	HX575 epoetin alfa (Sandoz)	—	COMPLETED	2014-10	NCT01576341
OPKO IP Holdings II, Inc.	CTAP101 30 μg capsules	—	COMPLETED	2014-08	NCT01704079
OPKO IP Holdings II, Inc.	CTAP101 30 μg capsules	—	COMPLETED	2014-07	NCT01651000
Pharmacosmos A/S	Monofer	—	COMPLETED	2014-06	NCT01102413
AbbVie (prior sponsor, Abbott)	Paricalcitol	Vitamin D2 Analog [EPC]	COMPLETED	2014-05	NCT01020487
Novartis	HX575 epoetin alfa	—	COMPLETED	2014-05	NCT01693029

Showing 100 of 180 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Ingenia Therapeutics INC	IGT-303	—	RECRUITING	2026-10	NCT07231679
AION Healthspan, Inc.	AION-301	—	RECRUITING	2027-01	NCT06721143
R1 Therapeutics	AP306 75 mg BID	—	RECRUITING	2027-02-28	NCT06712654
River 3 Renal Corp.	R3R01	—	RECRUITING	2027-04-01	NCT06600412
PT. Prodia Stem Cell Indonesia	Umbilical Cord Mesenchymal Stem Cells	—	RECRUITING	2027-07	NCT07396155
Regeneron	ALN-ANG3	—	RECRUITING	2028-10-13	NCT07271186
Vifor Fresenius Medical Care Renal Pharma	Difelikefalin	—	RECRUITING	2029-08-15	NCT06593392
The United Bio-Technology (Hengqin) Co., Ltd.	UBT251	—	RECRUITING	2030-07-11	NCT07134335
Novo Nordisk	NNC0519-0130	—	RECRUITING	2026-09-01	NCT06717698
Shaanxi Micot Pharmaceutical Technology Co., Ltd.	MT1013	—	RECRUITING	2025-08-19	NCT06976177
AstraZeneca	Zibotentan/Dapagliflozin	—	ACTIVE NOT RECRUITING	2026-09-26	NCT06942910
Regeneron	Vonsetamig	—	ACTIVE NOT RECRUITING	2027-11-22	NCT05092347
Shenzhen Salubris Pharmaceuticals Co., Ltd.	SAL0120 1mg	—	ACTIVE NOT RECRUITING	2026-05-27	NCT07716618
Biocity Biopharmaceutics Co., Ltd.	SC0062 low dose	—	ACTIVE NOT RECRUITING	2024-11-30	NCT05687890
PT. JES Kasih Nusantara Sejahterah	Dendritic cell immunotherapy	—	ACTIVE NOT RECRUITING	2024-08-05	NCT06866158
Novartis	Atrasentan	—	ACTIVE NOT RECRUITING	2024-07-02	NCT04573920
Eli Lilly	Clazakizumab	—	NOT YET RECRUITING	2027-05	NCT07783802
Shenzhen Salubris Pharmaceuticals Co., Ltd.	SAL0140 Tablets	—	NOT YET RECRUITING	2027-10-08	NCT07647133
Atom Therapeutics Co., Ltd	ABP-671 plus febuxostat Group 1	—	NOT YET RECRUITING	2027-10-31	NCT07323095
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-10390	—	NOT YET RECRUITING	2027-11-11	NCT07555054
Boehringer Ingelheim	Vicadrostat	—	COMPLETED	2026-08-14	NCT06926660
Eli Lilly	Tirzepatide	Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]	COMPLETED	2026-07-06	NCT05536804
Shanghai Hengrui Pharmaceutical Co., Ltd.	SHR6508	—	COMPLETED	2025-11-13	NCT06236295
Bayer	BAY3283142	—	COMPLETED	2025-10-24	NCT06522997
Eli Lilly	Retatrutide	—	COMPLETED	2025-10-01	NCT05936151
Novo Nordisk	Cagrilintide	—	COMPLETED	2025-09-24	NCT06131372
Shaanxi Micot Pharmaceutical Technology Co., Ltd.	MT1013	—	COMPLETED	2025-08-30	NCT06690242
Revelation Biosciences, Inc	Intravenous Gemini	—	COMPLETED	2025-07-22	NCT06863467
Prokidney	Renal Autologous Cell Therapy (REACT)	—	COMPLETED	2025-05-20	NCT05018416
Shaanxi Micot Pharmaceutical Technology Co., Ltd.	Long-term Dosing Cohort	—	COMPLETED	2025-05-12	NCT06747247
AstraZeneca	Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg	—	COMPLETED	2025-05-09	NCT06350123
Bayer	Finerenone (BAY94-8862 ) 10 mg	—	COMPLETED	2025-03-14	NCT05254002
Tourmaline Bio, Inc., a Novartis Company	TOUR006 - 50 MG	—	COMPLETED	2025-03-06	NCT06362759
Shandong Suncadia Medicine Co., Ltd.	HRS-1780 tablet；Henagliflozin Proline tablet；HRS-1780 tablet placebo ；Henagliflozin Proline tablet placebo	—	COMPLETED	2025-03-05	NCT06221059
Mineralys Therapeutics Inc.	Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD	—	COMPLETED	2025-02-27	NCT06150924
Shanghai Pharmaceuticals Holding Co., Ltd	SPH3127+SPH3127matching placebo+valsartan matching placebo	—	COMPLETED	2024-12-31	NCT05593575
Ebima Clifford Okundaye	QRX-3	—	COMPLETED	2024-08-30	NCT06948292
Inversago Pharma Inc.	INV-202	—	COMPLETED	2024-08-20	NCT05514548
Unicycive Therapeutics, Inc	Oxylanthanum Carbonate	—	COMPLETED	2024-05-29	NCT06218290
AstraZeneca	CIN-107	—	COMPLETED	2024-05-02	NCT05432167
MC2 Therapeutics	MC2-25 cream	—	COMPLETED	2024-02-02	NCT05482698
Prokidney	Renal Autologous Cell Therapy (REACT)	—	COMPLETED	2023-12	NCT02836574
Neurocrine UK Limited	Chronocort	—	COMPLETED	2023-10-18	NCT05222152
AstraZeneca	AZD9977	—	COMPLETED	2023-09-22	NCT04595370
Alebund Pharmaceuticals	AP-306	—	COMPLETED	2023-08-25	NCT05764590
Boehringer Ingelheim	Avenciguat	—	COMPLETED	2023-08-15	NCT04736628
AstraZeneca	Zibotentan	—	COMPLETED	2023-06-01	NCT04724837
AstraZeneca	MEDI3506	—	COMPLETED	2023-05-16	NCT04170543
Prokidney	Renal Autologous Cell Therapy (REACT)	—	COMPLETED	2022-11-17	NCT03270956
CSL Behring	CSL346	—	COMPLETED	2022-10-24	NCT04419467
AstraZeneca	Cotadutide 100 micrograms	—	COMPLETED	2022-03-08	NCT04515849
Bayer	runcaciguat	—	COMPLETED	2022-03-08	NCT04507061
Allena Pharmaceuticals	ALLN-346	—	COMPLETED	2022-03-02	NCT04987242
Xiamen Amoytop Biotech Co., Ltd.	YPEG-rhEPO	—	COMPLETED	2022-01-05	NCT04885647
Bayer	Finerenone (Kerendia, BAY94-8862)	—	COMPLETED	2021-12-31	NCT05013008
AstraZeneca	Verinurad	—	COMPLETED	2021-11-22	NCT03990363
Biogen	Bardoxolone methyl oral capsule	—	COMPLETED	2021-10-20	NCT04702997
Gilead	SEL	—	COMPLETED	2021-09-03	NCT04026165
Novo Nordisk	Ziltivekimab	—	COMPLETED	2021-08-03	NCT04626505
Roche	Mircera	Erythropoietin Receptor	COMPLETED	2021-07-19	NCT03552393
Novartis	Nidufexor	—	COMPLETED	2021-05-03	NCT03804879
KBP Biosciences	KBP-5074 0.25 mg tablet	—	COMPLETED	2020-08-05	NCT03574363
Dimerix Bioscience Pty Ltd	Propagermanium	—	COMPLETED	2020-07-23	NCT03627715
Novo Nordisk	Ziltivekimab	—	COMPLETED	2020-06-26	NCT03926117
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	COMPLETED	2020-06-05	NCT03799627
Kyntra Bio	Roxadustat	—	COMPLETED	2019-12-12	NCT01630889
Cara Therapeutics, Inc.	CR845 0.25 mg Oral Tablet	—	COMPLETED	2019-10-24	NCT03617536
Bayer	Fulacimstat (BAY1142524)	—	COMPLETED	2019-10-02	NCT03412006
Teijin America, Inc.	TMX-049	—	COMPLETED	2019-05-07	NCT03449199
UnicoCell Biomed CO. LTD	ELIXCYTE	—	COMPLETED	2019-04-23	NCT02933827
Pieris Pharmaceuticals GmbH	PRS-080#022-DP	—	COMPLETED	2019-03-30	NCT03325621
MedImmune LLC	MEDI0382	—	COMPLETED	2019-02-04	NCT03550378
Takeda	Lanthanum Carbonate	—	COMPLETED	2018-11-16	NCT01696279
Novartis	LHW090	—	COMPLETED	2018-10-11	NCT02678000
Fresenius Kabi	Ketosteril®	—	COMPLETED	2018-04-27	NCT03077048
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	COMPLETED	2017-10-24	NCT03054350
Tanabe Pharma Corporation	MT-3995 Low	—	COMPLETED	2017-08	NCT02676401
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	COMPLETED	2017-07-04	NCT03054337
Genexine, Inc.	GX-E2	—	COMPLETED	2017-04-20	NCT02044653
Vascular Pharmaceuticals, Inc.	VPI-2690B low dose	—	COMPLETED	2017-03	NCT02251067
Bayer	Molidustat (BAY85-3934)	—	COMPLETED	2016-11-15	NCT02055482
Tanabe Pharma Corporation	MT-3995 Low	—	COMPLETED	2016-11	NCT02517320
Astellas	ASP8232	—	COMPLETED	2016-10-26	NCT02358096
Bayer	Molidustat (BAY85-3934)	—	COMPLETED	2016-10-19	NCT02064426
Gilead	Selonsertib	—	COMPLETED	2016-07	NCT02177786
Aevi Genomic Medicine, LLC, a Cerecor company	MDGN201 TARGTEPO	—	COMPLETED	2016-06-30	NCT02117427
Daiichi Sankyo	CS-3150	—	COMPLETED	2016-06	NCT02345057
3-C Institute for Social Development	—	—	COMPLETED	2016-06	NCT02864641
Kyowa Kirin Co., Ltd.	RTA 402	—	COMPLETED	2016-05	NCT02316821
La Jolla Pharmaceutical Company	GCS-100	—	COMPLETED	2016-05	NCT02155673
Capricor Inc.	Cenderitide	—	COMPLETED	2016-03-31	NCT02603614
Mallinckrodt	Repository Corticotropin Injection	—	COMPLETED	2016-01	NCT01601236
Bayer	Molidustat (BAY 85-3934)	—	COMPLETED	2015-10-23	NCT01975818
Bayer	BAY85-3934	—	COMPLETED	2015-10-15	NCT02021409
Bayer	BAY85-3934	—	COMPLETED	2015-09-15	NCT02021370
Eli Lilly	LY3016859	—	COMPLETED	2015-08	NCT01774981
Tanabe Pharma Corporation	MT-3995	—	COMPLETED	2015-08	NCT02205372
Astellas	ASP1517	—	COMPLETED	2015-07-06	NCT01964196
AstraZeneca	Eculizumab	Complement Inhibitor [EPC]	COMPLETED	2015-06-11	NCT01567085
Genzyme, a Sanofi Company	Sevelamer carbonate	—	COMPLETED	2015-06	NCT01574326

Showing 100 of 167 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Bayer	Nurandociguat (BAY3283142) old tablet - SD	—	RECRUITING	2026-10-28	NCT07722585
Beijing Continent Pharmaceutical Co, Ltd.	Hydronidone capsules	—	RECRUITING	2026-12-01	NCT07262333
AstraZeneca	AZD4248	—	RECRUITING	2026-12-25	NCT07024823
EicOsis Human Health Inc.	EC5026 oral tablet	—	RECRUITING	2026-12-31	NCT07694544
Mediar Therapeutics	MTX-439	—	RECRUITING	2027-05	NCT07473323
Ono Pharmaceutical Co., Ltd.	ONO-3310	—	RECRUITING	2027-11-30	NCT07619157
Novartis	OJR520	—	RECRUITING	2028-01-21	NCT07235059
Alebund Pharmaceuticals	AP303 150μg	—	RECRUITING	2025-09-25	NCT06666283
Henan Genuine Biotech Co., Ltd.	Azvudine tablets	—	RECRUITING	2025-08-30	NCT07001436
Consun Pharmaceutical Group	SK-08	—	RECRUITING	2025-08-07	NCT07021157
Eli Lilly	LY3841136	—	ACTIVE NOT RECRUITING	2026-10	NCT07426380
Pulmongene Ltd.	PMG1016 Dose 1	—	NOT YET RECRUITING	2026-11-30	NCT07615985
Novo Nordisk	NNC0537-1482	—	NOT YET RECRUITING	2027-07-06	NCT07808788
Shandong Suncadia Medicine Co., Ltd.	[14C]HRS-1780	—	NOT YET RECRUITING	2026-06	NCT07557407
Klotho Sciences Australia Pty Ltd.	Part 1 KS101	—	NOT YET RECRUITING	2026-04-01	NCT07143331
R3 Stem Cell	Amniotic and Umbilical Cord Tissue Procedure	—	NOT YET RECRUITING	2024-03-20	NCT03899298
Eli Lilly	LY3537031	—	COMPLETED	2026-04-16	NCT07165015
Eli Lilly	LY3537982	—	COMPLETED	2026-04-10	NCT07137689
EHL Bio Co., Ltd.	KDSTEM Inj.	—	COMPLETED	2026-03-09	NCT06071143
Bayer	BAY3283142	—	COMPLETED	2025-11-21	NCT06428825
Novo Nordisk	NNC0705-0001	—	COMPLETED	2025-11-04	NCT07029568
AstraZeneca	AZD4144	—	COMPLETED	2025-10-27	NCT06675175
Disc Medicine, Inc	DISC-0974	—	COMPLETED	2025-10-09	NCT05745883
Bayer	BAY3283142	—	COMPLETED	2025-02-24	NCT06402721
Biocodex	STIRIPENTOL oral administration	—	COMPLETED	2024-11-30	NCT05735951
Bayer	BAY3283142	—	COMPLETED	2024-09-19	NCT06487845
Eli Lilly	LY3473329	—	COMPLETED	2024-09-06	NCT05778864
Novo Nordisk	Ziltivekimab	—	COMPLETED	2024-06-12	NCT05379829
Eli Lilly	LY3502970	—	COMPLETED	2024-04-11	NCT05936138
AdAlta Limited	AD-214	—	COMPLETED	2024-02-09	NCT05914909
Incyte Corporation	INCB054707	—	COMPLETED	2024-02-07	NCT05624723
Eli Lilly	LY3819469	—	COMPLETED	2024-01-09	NCT05841277
Haisco Pharmaceutical Group Co., Ltd.	HSK21542 Injection	—	COMPLETED	2023-11-21	NCT06238388
Boehringer Ingelheim	BI 425809	—	COMPLETED	2023-10-24	NCT05718843
Pharmicell Co., Ltd.	Cellgram-CKD	—	COMPLETED	2023-09-21	NCT05042206
Eli Lilly	LY3437943	—	COMPLETED	2023-09-05	NCT05611957
Sunshine Lake Pharma Co., Ltd.	HEC53856	—	COMPLETED	2023-08-29	NCT04925661
Boehringer Ingelheim	BI 1015550	—	COMPLETED	2023-08-15	NCT05718648
Bayer	BAY3283142	—	COMPLETED	2023-07-19	NCT05800444
Incyte Corporation	INCB054707	—	COMPLETED	2023-06-30	NCT05624710
Bayer	Single oral dose of BAY3283142 IR (immediate release) tablet	—	COMPLETED	2023-03-07	NCT05515432
Prokidney	Renal Autologous Cell Therapy (REACT)	—	COMPLETED	2023-01-31	NCT04115345
Lisata Therapeutics, Inc.	CLBS201	—	COMPLETED	2023-01-26	NCT04990427
Bristol-Myers Squibb	Iberdomide	—	COMPLETED	2023-01-23	NCT04933747
Sunshine Lake Pharma Co., Ltd.	HEC73077 tablets	—	COMPLETED	2023-01-04	NCT05492630
Bayer	BAY3283142	—	COMPLETED	2023-01-03	NCT05491642
Nanogen Pharmaceutical Biotechnology Joint Stock Company	Stimus	—	COMPLETED	2022-11-23	NCT05636891
AstraZeneca	cotadutide solution for injection	—	COMPLETED	2022-09-12	NCT05294458
AN2 Therapeutics, Inc	Epetraborole	—	COMPLETED	2022-06-10	NCT05283746
Zydus Lifesciences Limited	Desidustat	—	COMPLETED	2022-03-27	NCT04667533
AstraZeneca	Zibotentan (Treatment A)	—	COMPLETED	2021-10-22	NCT04991571
Pfizer	Aztreonam-Avibactam	—	COMPLETED	2021-09-20	NCT04486625
AstraZeneca	Verinurad prolonged release HPMC capsule	—	COMPLETED	2021-07-15	NCT04550234
VectivBio AG	Apraglutide	—	COMPLETED	2021-07-05	NCT04699032
Eli Lilly	Pirtobrutinib	Kinase Inhibitor [EPC]	COMPLETED	2021-06-04	NCT06190678
Jiangsu HengRui Medicine Co., Ltd.	DDO-3055	—	COMPLETED	2021-05-11	NCT03976115
Rhythm Pharmaceuticals, Inc.	Setmelanotide	—	COMPLETED	2021-04-17	NCT04348175
AstraZeneca	AZD5718	—	COMPLETED	2021-03-25	NCT04734275
Takeda	Azacitidine	Nucleoside Metabolic Inhibitor [EPC]	COMPLETED	2021-03-19	NCT03814005
AstraZeneca	MEDI8367	—	COMPLETED	2021-01-03	NCT04365218
AstraZeneca	Verinurad	—	COMPLETED	2020-11-23	NCT04532918
Boehringer Ingelheim	BI 764198	—	COMPLETED	2020-11-17	NCT04176536
Idorsia Pharmaceuticals Ltd.	ACT-541468	—	COMPLETED	2020-08-14	NCT04024332
Renibus Therapeutics, Inc.	RBT-9	—	COMPLETED	2020-07-31	NCT04072861
Akebia Therapeutics	Vadadustat	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	COMPLETED	2020-05-05	NCT03992066
Renibus Therapeutics, Inc.	RBT-1	—	COMPLETED	2020-04-22	NCT03893799
Ensoma	MGTA-145	—	COMPLETED	2020-03-24	NCT04154670
Genfit	Elafibranor	Peroxisome Proliferator-activated Receptor Agonist [EPC]	COMPLETED	2020-03-15	NCT03844555
Bayer	Copanlisib (ALIQOPA, BAY80-6946)	—	COMPLETED	2020-03-13	NCT03172884
Jiangsu HengRui Medicine Co., Ltd.	DDO-3055 tablet	—	COMPLETED	2020-01-18	NCT04197778
AstraZeneca	Verinurad ER8 capsule formulation (fasted)	—	COMPLETED	2019-09-18	NCT04024501
Eli Lilly	Tirzepatide	Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]	COMPLETED	2019-08-19	NCT03482024
Eli Lilly	Selpercatinib	Kinase Inhibitor [EPC]	COMPLETED	2019-08-07	NCT05469100
DiaMedica Therapeutics Inc	DM199	—	COMPLETED	2019-07-21	NCT03795389
AstraZeneca	Verinurad	—	COMPLETED	2019-04-26	NCT03836599
Renibus Therapeutics, Inc.	RBT-3	—	COMPLETED	2019-03-31	NCT04072432
Guerbet	P03277	—	COMPLETED	2019-02-01	NCT03657784
Amgen	Etelcalcetide	CaSR	COMPLETED	2018-10-31	NCT02833857
Boehringer Ingelheim	BI 1467335	—	COMPLETED	2018-08-16	NCT03302091
Novartis	QAW039	—	COMPLETED	2018-08-07	NCT03087942
Merck	Midazolam oral solution	—	COMPLETED	2018-08-02	NCT03311841
MedImmune LLC	MEDI0382	—	COMPLETED	2018-04-24	NCT03235375
Johnson & Johnson	Odalasvir	—	COMPLETED	2018-04-09	NCT02961660
Bristol-Myers Squibb	CC-122	—	COMPLETED	2017-12-23	NCT03097016
Janssen Pharmaceutica N.V., Belgium	JNJ-64041575	—	COMPLETED	2017-12-06	NCT03189498
Merck	Gefapixant	—	COMPLETED	2017-09-03	NCT03108924
Johnson & Johnson	AL-335	—	COMPLETED	2017-08-08	NCT02894905
Sarfez Pharmaceuticals, Inc.	Demadex 20mg Tablet	—	COMPLETED	2017-07-20	NCT03214874
Taisho Pharmaceutical Co., Ltd.	TS-143	—	COMPLETED	2017-07-06	NCT03581071
Rockwell Medical Technologies, Inc.	Triferic	—	COMPLETED	2017-07	NCT02909153
Bayer	BAY1841788	—	COMPLETED	2017-04-10	NCT02894385
KBP Biosciences	KBP-5074	—	COMPLETED	2016-12-20	NCT02837237
Akros Pharma Inc.	JTZ-951, 14C-JTZ-951	—	COMPLETED	2016-09	NCT02805244
Eli Lilly	LY3113593	—	COMPLETED	2016-06-22	NCT02604160
KBP Biosciences	KBP-5074	—	COMPLETED	2016-05-26	NCT02653014
Akros Pharma Inc.	JTZ-951	—	COMPLETED	2016-04	NCT02581124
Gilead	Selonsertib	—	COMPLETED	2015-12-15	NCT02509624
Bayer	Molidustat(BAY85-3934)	—	COMPLETED	2015-12-02	NCT02312973
Prolong Pharmaceuticals	SANGUINATE	—	COMPLETED	2015-11-18	NCT02437422
Eli Lilly	LY2928057	—	COMPLETED	2015-10	NCT01991483

Novel Chronic Kidney Disease Drugs by Company (New molecular entities)

5 companies have an FDA-approved novel drug for Chronic Kidney Disease.

KAI PHARMS INC 1 drug

PARSABIV

ETELCALCETIDE

NDA 2017

LEXICON PHARMS INC 1 drug

Amgen 1 drug

HOFFMAN-LA ROCHE 1 drug

MIRCERA

METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA

AKEBIA 1 drug

Reformulations (17 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Chronic Kidney Disease Drug Targets

Molecular targets of approved and investigational Chronic Kidney Disease drugs — 16 targets tracked.

SGLT2 6 Erythropoietin Receptor 3 VDR 2 Transferrin 2 CaSR 1 SGLT1 1 ferric reductase 1 phosphate 1 CYP27B1 1 Vitamin D receptor 1 hepatic glucose production 1 insulin sensitivity 1 intestinal absorption of glucose 1 Kappa opioid receptor 1 HIF-prolyl-4-hydroxylases 1 +1 more

Biosimilars (1 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.

RETACRIT

Pfizer

2018

Generic Drugs (5 ANDA approved) Click to expand

Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).

SEVELAMER HYDROCHLORIDE